PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.12%
Both companies show declining cash positions (-5.12% vs TRVN's -14.91%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-5.12%
Below half of TRVN's -14.91%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
820.83%
Other current assets growth < half of TRVN's -38.25%. David Dodd sees a leaner approach to short-term items.
-4.22%
Below half of TRVN's -14.18%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-17.65%
≥ 1.5x TRVN's -3.18%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRVN and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of TRVN's 31.77%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-47.54%
Below half of TRVN's 1.70%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Below half of TRVN's -12.57%. Michael Burry sees a potential red flag for stagnation or capital shortage.
46.70%
Similar yoy growth to TRVN's 53.15%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
-26.38%
Less than half of TRVN's 2.86%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
126.45%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
265.71%
Similar yoy changes to TRVN's 274.03%. Walter Schloss finds parallel near-term liability trends.
63.25%
Above 1.5x TRVN's 23.85%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Above 1.5x TRVN's -3.18%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Above 1.5x TRVN's 11.21%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
1.25-1.5x TRVN's -2.91%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.40%
Below half TRVN's -16.84%. Michael Burry sees potential underperformance in building shareholder capital.
-4.84%
Below half TRVN's -12.57%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both TRVN and the company show zero Total Investments Growth.
-26.37%
Above 1.5x TRVN's -2.54%. Michael Burry sees a major jump. Investigate leverage rationale.
5.01%
Less than half of TRVN's 16.17%. David Dodd sees better deleveraging or stronger cash buildup than competitor.